{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:50:55Z","timestamp":1772866255060,"version":"3.50.1"},"reference-count":70,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of four cohorts of patients with\n                      <jats:italic toggle=\"yes\">ATM<\/jats:italic>\n                      -altered tumors treated with olaparib are reported: colorectal cancer (CRC), lung cancer (LC), pancreatic cancer (PC), and other solid tumors (histology-pooled, HP).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks duration. For histology-specific cohorts, Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85;\n                      <jats:italic toggle=\"yes\">\u03b1<\/jats:italic>\n                      = .10). For the HP cohort, the hypothesized null DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was &gt;15%. Secondary end points were OR, progression-free survival, overall survival, duration of response or SD, and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Patients with CRC (n = 30), LC (n = 20), PC (n = 28), or other advanced cancers (n = 38) with\n                      <jats:italic toggle=\"yes\">ATM<\/jats:italic>\n                      alterations were enrolled. The DC rates were 23% (one-sided 90% CI, 8 to 100;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .38), 45% (one-sided 90% CI, 32 to 100;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0004), 28% (one-sided 90% CI, 14 to 100;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .14), and 25% (one-sided 90% CI, 16 to 100), respectively. The null hypothesized 15% DC rate was rejected for the LC and HP cohorts but not the CRC and PC cohorts. Twenty of 116 patients (17%) experienced treatment-related grade 3 adverse events (AE) or serious AEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      Olaparib met the prespecified criteria to declare a signal of activity in patients with\n                      <jats:italic toggle=\"yes\">ATM<\/jats:italic>\n                      -altered cancer within the LC and HP cohorts but not the CRC or PC cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-00716","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:59:11Z","timestamp":1768510751000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Olaparib in Patients With Solid Tumors With\n                    <i>ATM<\/i>\n                    Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study"],"prefix":"10.1200","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02693535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1347-4232","authenticated-orcid":true,"given":"Daniel R.","family":"Carrizosa","sequence":"first","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-6742","authenticated-orcid":true,"given":"Pam K.","family":"Mangat","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0333","authenticated-orcid":true,"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-5055","authenticated-orcid":true,"given":"Deepti","family":"Behl","sequence":"additional","affiliation":[{"name":"Sutter Cancer Research Consortium, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bamidele","family":"Adesunloye","sequence":"additional","affiliation":[{"name":"City of Hope - Atlanta, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Pisick","sequence":"additional","affiliation":[{"name":"City of Hope - Chicago, Zion, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9637-0359","authenticated-orcid":true,"given":"Kathleen W.","family":"Beekman","sequence":"additional","affiliation":[{"name":"Trinity Health IHA Medical Group, Ypsilanti, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-512X","authenticated-orcid":true,"given":"Efrat","family":"Dotan","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-7722","authenticated-orcid":true,"given":"Mehmet","family":"Akce","sequence":"additional","affiliation":[{"name":"O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-4725","authenticated-orcid":true,"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-1548","authenticated-orcid":true,"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-8520","authenticated-orcid":true,"given":"Kelsey A.","family":"Klute","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-141X","authenticated-orcid":true,"given":"Jeanny B.","family":"Aragon-Ching","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute, Fairfax, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrine A.","family":"Cooper","sequence":"additional","affiliation":[{"name":"The Cancer and Hematology Centers, Grand Rapids, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-9924","authenticated-orcid":true,"given":"Ramya","family":"Thota","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare, Murray, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":true,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8537-6397","authenticated-orcid":true,"given":"Peter J.","family":"Hosein","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika C.","family":"Maestas","sequence":"additional","affiliation":[{"name":"University of New Mexico Comprehensive Cancer Center, Albuquerque, NM"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-1652","authenticated-orcid":false,"given":"Justin T.","family":"Moyers","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5029-0048","authenticated-orcid":true,"given":"Steven","family":"Powell","sequence":"additional","affiliation":[{"name":"Sanford Health, Sioux Falls, SD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-3288","authenticated-orcid":true,"given":"Song","family":"Zhao","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-0131","authenticated-orcid":true,"given":"Evthokia","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Providence Health and Services, Portland, OR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-025X","authenticated-orcid":true,"given":"Jens","family":"Rueter","sequence":"additional","affiliation":[{"name":"Jackson Laboratory-Maine Cancer Genomics Initiative, Bar Harbor, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-8403","authenticated-orcid":true,"given":"Davendra P. S.","family":"Sohal","sequence":"additional","affiliation":[{"name":"University of Cincinnati Cancer Center, Cincinnati, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Lewis Cancer and Research Pavilion, Savannah, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-9484","authenticated-orcid":true,"given":"Dominique C.","family":"Hinshaw","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4369","authenticated-orcid":true,"given":"Abigail","family":"Gregory","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0419","authenticated-orcid":true,"given":"Gina N.","family":"Grantham","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":true,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-4303","authenticated-orcid":true,"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13285"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes12091370"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes12060845"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00394-2"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030687"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092042"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2067527"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102111"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040435"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21870"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00339"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01604"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.005"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0887"},{"key":"e_1_3_11_18_2","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","author":"Shroff RT","unstructured":"Shroff RT, Hendifar A, McWilliams RR, et al: Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol 10.1200\/PO.17.00316","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00003"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214676"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.29212"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3126"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.01.007"},{"key":"e_1_3_11_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102041"},{"key":"e_1_3_11_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5218"},{"key":"e_1_3_11_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0006"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30682-4"},{"key":"e_1_3_11_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102623"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02105"},{"key":"e_1_3_11_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02151"},{"key":"e_1_3_11_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30684-9"},{"key":"e_1_3_11_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3116"},{"key":"e_1_3_11_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0007"},{"key":"e_1_3_11_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_3_11_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0320"},{"key":"e_1_3_11_39_2","article-title":"Rationale and design of the Targeted Agent and Profiling Utilization Registry study","author":"Mangat PK","unstructured":"Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.18.00122","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_40_2","article-title":"Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Klute KA","unstructured":"Klute KA, Rothe M, Garrett-Mayer E, et al: Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.22.00191","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_41_2","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study","author":"Gupta R","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, et al: Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00306","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_42_2","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study","author":"Yang ES","unstructured":"Yang ES, Halabi S, Rothe M, et al: Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00505","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02923"},{"key":"e_1_3_11_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00753-7"},{"key":"e_1_3_11_45_2","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Al Baghdadi T","unstructured":"Al Baghdadi T, Halabi S, Garrett-Mayer E, et al: Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.19.00124","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_46_2","article-title":"Palbociclib in patients with non-small-cell lung cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Ahn ER","unstructured":"Ahn ER, Mangat PK, Garrett-Mayer E, et al: Palbociclib in patients with non-small-cell lung cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.20.00037","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00752-8"},{"key":"e_1_3_11_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00702"},{"key":"e_1_3_11_49_2","article-title":"Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.23.00240","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_50_2","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Rohatgi N","unstructured":"Rohatgi N, Rothe M, Mangat PK, et al: Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00279","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_51_2","article-title":"Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Calfa CJ","unstructured":"Calfa CJ, Rothe M, Mangat PK, et al: Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.23.00513","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_52_2","article-title":"Regorafenib in patients with solid tumors with BRAF alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Sahai V","unstructured":"Sahai V, Rothe M, Mangat PK, et al: Regorafenib in patients with solid tumors with BRAF alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00527","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02078"},{"key":"e_1_3_11_54_2","article-title":"Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Srkalovic G","unstructured":"Srkalovic G, Rothe M, Mangat PK, et al: Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.24.00026","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_11_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0435-8"},{"key":"e_1_3_11_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_3_11_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3123"},{"key":"e_1_3_11_59_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-1883"},{"key":"e_1_3_11_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1122"},{"key":"e_1_3_11_61_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2370"},{"key":"e_1_3_11_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03318"},{"key":"e_1_3_11_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.09.018"},{"key":"e_1_3_11_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107216"},{"key":"e_1_3_11_65_2","doi-asserted-by":"publisher","DOI":"10.21037\/cco-23-58"},{"key":"e_1_3_11_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101595"},{"key":"e_1_3_11_67_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-853"},{"key":"e_1_3_11_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0565-8"},{"key":"e_1_3_11_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv095.7"},{"key":"e_1_3_11_70_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1216824110"},{"key":"e_1_3_11_71_2","article-title":"Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations)","author":"Mahdi H","unstructured":"Mahdi H, Navid H, Doroshow D, et al: Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations). JCO Precis Oncol 10.1200\/PO.20.00439","journal-title":"JCO Precis Oncol"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:48:07Z","timestamp":1772812087000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/PO-25-00716"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00716","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500716"}}